Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 5/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632712 | 0.93 | REN (0.51) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL2735610 | 0.91 | PSMB5 (0.52) | PSMB5CTSLCTSB | |
| SCHEMBL17452195 | 0.88 | CTSS (0.63) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL2735611 | 0.88 | PSMB5 (0.49) | CTSSCTSKPSMB5CTSLCTSB | |
| SCHEMBL8270564 | 0.87 | CTSS (0.56) | CTSSCTSKPSMB5CTSLCTSB | |
| SCHEMBL28372334 | 0.86 | REN (0.62) | CTSSCTSKRENPSEN1PSEN2 | |
| SCHEMBL30485379 | 0.86 | REN (0.62) | CTSSCTSKRENPSEN1PSEN2 | |
| SCHEMBL8080979 | 0.86 | REN (0.62) | CTSSCTSKRENPSEN1PSEN2 | |
| SCHEMBL28372331 | 0.86 | REN (0.62) | CTSSCTSKRENPSEN1PSEN2 | |
| SCHEMBL28373438 | 0.86 | REN (0.62) | CTSSCTSKRENPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8088741-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088741-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | CTSS 107/4885CTSK 122/4885PSMB5 25/4885 |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | CTSS 65/4885CTSK 79/4885PSMB5 29/4885 |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | CTSS 65/4885CTSK 79/4885PSMB5 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.